[3] During his doctoral studies, Haraldsson began his clinical career as a part-time physician in emergency rooms in Borås, Vänersborg, Bäckefors, and Lysekil.

Moreover, he chaired several Swedish Research Council’s expert panels, and served as scientific secretary of the Gothenburg Medical Association.

After working there as a translational medicine expert in the ATI department for 3 years, he became Global Program Head in immunology, hepatology and dermatology (IHD) in 2018.

Haraldsson has focused his research on kidney disease, with particular attention on the properties of the glomerular barrier crucial for whole-body homeostasis and survival.

[12] In a study conducted in 1993, he discussed the application of plasma glycoprotein orosomucoid in regulating the dynamic properties of the glomerular capillary wall by reducing the permeability towards macromolecules.

[13] He developed a computer model for individualized therapy of patients with PD,[14] and regarded total pore area over diffusion distance (A(0)/Deltax) to be the significant parameter to describe exchange across the peritoneal membrane.

[15] Haraldsson’s research group published a series of papers focused on the understanding of the glomerular barrier, its properties, and the role of its individual components.

[16][17] In a paper published in 1992, he highlighted the role of orosomucoid in terms of maintenance of normal capillary permeability in skeletal muscle and mesentery.

[25] Their studies also suggested the usage of orellanine in terms of eliminating human renal cancer carcinomas with its highly organ-specific cytotoxic properties.